Don’t Stop Relieving: Journey’s DFD-29 Trounces Oracea In Reducing Rosacea Lesions

The company posted positive topline results from the Phase III MVOR-1 and MVOR-2 trials comparing DFD-29 against Galderma’s drug in papulopustular rosacea.

Journey announced topline results from two Phase III rosacea trials • Source: Shutterstock

Journey Medical Corp.’s DFD-29, partnered with Dr. Reddy's Laboratories Ltd., has potential to claim a significant share of the papulopustular rosacea market, which Galderma S.A.’s Oracea (doxycycline) currently dominates, having originally won US Food and Drug Administration approval in 1967. Topline results from Phase III clinical trials showed a statistically significant efficacy advantage for the drug over both Oracea and placebo in terms of reducing lesion count in adult patients with the skin condition.

More from Clinical Trials

Cerevance To Focus On Parkinson’s Adjunctive Therapy After Phase II Miss

 
• By 

After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.

Baxdrostat, AstraZeneca’s Next Big CVRM Bet

 
• By 

The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.

Merck’s Winrevair Slashes Morbidity-Mortality Risk For PAH Patients

 

The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.

Vertex Ends One Type 1 Diabetes Cell Therapy, Shifts Focus To Another

 
• By 

Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.

More from R&D

Corcept’s Relacorilant Shows Benefit In Ovarian Cancer, Expanding Pipeline Opportunity

 

A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.

AstraZeneca Oral PCSK9 Prospects Pumped After Phase IIb Win

 
• By 

The UK giant is forecasting peak sales of $5bn plus

Novo Scores Cardio Wins But Lilly Still Tipped To Take GLP-1 Crown

 

Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.